Zou Yuanyuan, Tuo Fei, Zhang Zhiqi, Guo Jiawen, Yuan Yueming, Zhang Hongying, Xu Zhiyong, Pan Ziyi, Tang Yexiao, Deng Changsheng, Julie Nadia, Wu Wanting, Guo Wenfeng, Li Changqing, Huang Xinan, Xu Qin, Song Jianping, Wang Qi
Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
Institute of Science and Technology, Guangzhou University of Chinese Medicine, Guangzhou, China.
Front Pharmacol. 2020 Nov 12;11:596697. doi: 10.3389/fphar.2020.596697. eCollection 2020.
The purpose of this meta-analysis of longitudinal studies is to determine the safety and efficacy of artesunate combined with other forms of adjunctive therapies for severe malaria. Following the PRISMA guidelines, we searched multiple databases with the search terms "artesunate" and "adjunctive therapy" and "severe malaria" in July 2020. If the search showed a randomized controlled trial, the study was included in this meta-analysis. The random-effects model was used to calculate the combined incidence rate and relative risk or risk difference. This meta-analysis included nine longitudinal studies with 724 participants. We found that the mortality rates in the artesunate monotherapy group and the artesunate + adjuvant therapy group are similar (RD = -0.02, 95% confidence interval: -0.06-0.02). The incidence of adverse reactions in the artesunate monotherapy group and the artesunate + adjuvant therapy group was also similar. No significant differences in safety and efficacy were observed between the artesunate monotherapy group and the artesunate + adjuvant therapy group. Higher quality and rigorously designed randomized controlled studies are needed to validate our findings.
这项纵向研究的荟萃分析旨在确定青蒿琥酯联合其他形式辅助疗法治疗重症疟疾的安全性和有效性。遵循PRISMA指南，我们于2020年7月在多个数据库中使用搜索词“青蒿琥酯”、“辅助疗法”和“重症疟疾”进行检索。如果检索结果显示为随机对照试验，则该研究纳入本荟萃分析。采用随机效应模型计算合并发病率以及相对风险或风险差异。本荟萃分析纳入了9项纵向研究，共724名参与者。我们发现，青蒿琥酯单药治疗组和青蒿琥酯+辅助治疗组的死亡率相似（风险差异=-0.02，95%置信区间：-0.06-0.02）。青蒿琥酯单药治疗组和青蒿琥酯+辅助治疗组的不良反应发生率也相似。青蒿琥酯单药治疗组和青蒿琥酯+辅助治疗组在安全性和有效性方面未观察到显著差异。需要更高质量且设计严谨的随机对照研究来验证我们的研究结果。
